Clinical data | |
---|---|
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
IUPAC name
| |
CAS Number |
|
PubChem CID |
|
ChemSpider |
|
UNII |
|
KEGG |
|
ChEMBL |
|
CompTox Dashboard (EPA) |
|
Chemical and physical data | |
Formula | C21H28N4O5 |
Molar mass | 416.478 g·mol−1 |
3D model (JSmol) |
|
SMILES
| |
InChI
|
Aderbasib (codenamed INCB7839) is a sheddase inhibitor that may suppress tumor cell proliferation.[1] Acting on multiple receptor classes and subclasses, aderbasib is observed to regulate the tumor necrosis factor of cancer cells.[2] Aderbasib was being developed by Incyte as a potential adjunctive treatment for metastatic breast cancer. Development was halted in 2011 after positive findings from Phase II trials were contradicted by further research.[3][4]